SG Americas Securities LLC Sells 56,985 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

SG Americas Securities LLC cut its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 74.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,303 shares of the company's stock after selling 56,985 shares during the period. SG Americas Securities LLC's holdings in EyePoint Pharmaceuticals were worth $154,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. RA Capital Management L.P. acquired a new position in EyePoint Pharmaceuticals during the 1st quarter worth $19,401,000. Point72 Asset Management L.P. acquired a new position in EyePoint Pharmaceuticals during the 2nd quarter worth $5,488,000. Cubist Systematic Strategies LLC lifted its holdings in EyePoint Pharmaceuticals by 842.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 476,250 shares of the company's stock worth $4,143,000 after buying an additional 425,717 shares in the last quarter. Vanguard Group Inc. lifted its holdings in EyePoint Pharmaceuticals by 17.8% during the 1st quarter. Vanguard Group Inc. now owns 2,396,228 shares of the company's stock worth $49,530,000 after buying an additional 362,168 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C lifted its holdings in EyePoint Pharmaceuticals by 51.4% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 877,790 shares of the company's stock worth $7,637,000 after buying an additional 298,196 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on EYPT. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of EyePoint Pharmaceuticals in a report on Friday. Scotiabank began coverage on EyePoint Pharmaceuticals in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $18.00 price target on the stock. StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a research note on Saturday, September 21st. JPMorgan Chase & Co. cut their price target on EyePoint Pharmaceuticals from $32.00 to $29.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 13th. Finally, Chardan Capital reissued a "buy" rating and issued a $28.00 price target on shares of EyePoint Pharmaceuticals in a research note on Friday, June 28th. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, EyePoint Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $29.00.

EyePoint Pharmaceuticals Stock Down 0.6 %

EyePoint Pharmaceuticals stock traded down $0.06 during mid-day trading on Friday, hitting $9.50. 374,930 shares of the company's stock were exchanged, compared to its average volume of 907,298. The firm has a market capitalization of $508.44 million, a P/E ratio of -5.30 and a beta of 1.57. EyePoint Pharmaceuticals, Inc. has a fifty-two week low of $5.67 and a fifty-two week high of $30.99. The company's 50 day simple moving average is $8.87 and its 200-day simple moving average is $10.75.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.03). The business had revenue of $9.48 million for the quarter, compared to analyst estimates of $11.61 million. EyePoint Pharmaceuticals had a negative return on equity of 43.24% and a negative net margin of 172.29%. Research analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.